Revolution Medicines Insider Sells $18.7M via 10b5-1 Plan
Revolution Medicines, Inc.
Subscribe to track RVMD
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
# Insider Transaction Alert: Revolution Medicines, Inc. ($RVMD)
**Insider:** Kelsey Stephen Michael
**Title:** Senior Advisor to the Chief Executive Officer
**Filing Date:** 2026-09-15 | **Transaction Date:** 2026-09-11
### Transaction Summary
* **Action:** Option Exercise & Sale (Rule 10b5-1 Plan)
* **Shares Sold:** 92,531
* **Average Sale Price:** ~$202.36
* **Total Sale Proceeds:** ~$18,724,767.48
* **Shares Remaining:** 291,876 (including 76,251 RSUs)
Comprehensive Analysis
Executive Summary
On September 11, 2026, Stephen Michael Kelsey, Senior Advisor to the CEO of Revolution Medicines, Inc. ($RVMD), executed derivative exercises and sales totaling 92,531 shares of Common Stock for aggregate proceeds of approximately $18.72 million. Following these transactions, Dr. Kelsey directly retains 291,876 shares (including 76,251 restricted stock units).
Transaction Details
- Option Exercises:
- Exercised 52,500 options at an exercise price of $42.45 per share.
- Exercised 40,031 options at an exercise price of $40.74 per share.
- Open Market Sales:
- Sold 92,531 shares in multiple tranches at weighted average prices ranging from $198.55 to $205.81 per share.
- Rule 10b5-1 Plan: All transactions were pre-planned and executed under a Rule 10b5-1 trading plan adopted on June 12, 2026.
Context & Significance
The transactions reflect standard liquidity management and option monetization under an established Rule 10b5-1 trading arrangement. Due to the pre-scheduled nature of the plan and substantial retained equity holding (291,876 shares), the trading significance is categorized as Medium.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.